Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Day One Biopharmaceuticals Inc’s stock clocked out at $6.76, down -5.98% from its previous closing price of $7.19. In other words, the price has decreased by -$5.98 from its previous closing price. On the day, 1.04 million shares were traded. DAWN stock price reached its highest trading level at $7.21 during the session, while it also had its lowest trading level at $6.63.
Ratios:
To gain a deeper understanding of DAWN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.61 and its Current Ratio is at 7.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when York Charles N II sold 4,370 shares for $11.96 per share. The transaction valued at 52,278 led to the insider holds 252,638 shares of the business.
Dubow Adam sold 4,646 shares of DAWN for $55,580 on Feb 18 ’25. The GENERAL COUNSEL now owns 39,602 shares after completing the transaction at $11.96 per share. On Feb 18 ’25, another insider, Bender Jeremy, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 12,048 shares for $11.96 each. As a result, the insider received 144,130 and left with 128,015 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 685153088 and an Enterprise Value of 156038528. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.22 while its Price-to-Book (P/B) ratio in mrq is 1.36. Its current Enterprise Value per Revenue stands at 1.19 whereas that against EBITDA is -0.741.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.18, which has changed by -0.5707936 over the last 52 weeks, in comparison to a change of 0.05279863 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $6.41. The 50-Day Moving Average of the stock is -26.79%, while the 200-Day Moving Average is calculated to be -46.70%.
Shares Statistics:
It appears that DAWN traded 1.17M shares on average per day over the past three months and 1212590 shares per day over the past ten days. A total of 101.12M shares are outstanding, with a floating share count of 74.28M. Insiders hold about 26.71% of the company’s shares, while institutions hold 83.54% stake in the company. Shares short for DAWN as of 1743379200 were 17481507 with a Short Ratio of 14.99, compared to 1740700800 on 18177016. Therefore, it implies a Short% of Shares Outstanding of 17481507 and a Short% of Float of 20.809999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
